Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−27.3745 EUR
−68.46 M EUR
6.89 M EUR
6.34 M
About Tvardi Therapeutics, Inc.
Sector
Industry
CEO
Imran Alibhai
Website
Headquarters
Sugar Land
Founded
2017
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company was founded in 2017 and is headquartered in Sugar Land, TX.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on LSX exchange Tvardi Therapeutics Inc. stocks are traded under the ticker A414VY.
We've gathered analysts' opinions on Tvardi Therapeutics Inc. future price: according to them, A414VY price has a max estimate of 66.74 EUR and a min estimate of 35.08 EUR. Watch A414VY chart and read a more detailed Tvardi Therapeutics Inc. stock forecast: see what analysts think of Tvardi Therapeutics Inc. and suggest that you do with its stocks.
A414VY stock is 1.16% volatile and has beta coefficient of 0.33. Track Tvardi Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Tvardi Therapeutics Inc. there?
Today Tvardi Therapeutics Inc. has the market capitalization of 182.96 M, it has increased by 37.21% over the last week.
Yes, you can track Tvardi Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Tvardi Therapeutics Inc. is going to release the next earnings report on Aug 5, 2025. Keep track of upcoming events with our Earnings Calendar.
A414VY earnings for the last quarter are −2.98 EUR per share, whereas the estimation was −0.54 EUR resulting in a −450.43% surprise. The estimated earnings for the next quarter are −0.60 EUR per share. See more details about Tvardi Therapeutics Inc. earnings.
Tvardi Therapeutics Inc. revenue for the last quarter amounts to 2.37 M EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
A414VY net income for the last quarter is −4.53 M EUR, while the quarter before that showed −7.42 M EUR of net income which accounts for 38.87% change. Track more Tvardi Therapeutics Inc. financial stats to get the full picture.
No, A414VY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 17, 2025, the company has 10 employees. See our rating of the largest employees — is Tvardi Therapeutics Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Tvardi Therapeutics Inc. EBITDA is −28.43 M EUR, and current EBITDA margin is −778.88%. See more stats in Tvardi Therapeutics Inc. financial statements.
Like other stocks, A414VY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Tvardi Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.